Micardis hct form.
The medicine is white tablets, oblong, with an engraving “51N” on one edge and a company logo on the other side.
7 such tablets with a dosage of 40 mg are in a blister, 2 or 4 such blisters in a cardboard bundle. Either 7 such tablets with a dosage of 80 mg are in a blister, 2, 4 or 8 such blisters in a cardboard bundle.
Pharmacological action of Micardis hct.
Suppression of angiotensin II and, as a consequence, vasodilation. The drug lowers blood pressure, the content of aldosterone in the blood. Micardis hct can be purchased on our website.
Pharmacodynamics and pharmacokinetics of Micardis hct
Telmisartan is a selective blocker of angiotensin II receptors. Has a high tropism for the AT1 subtype of angiotensin II receptors. It is competing with angiotensin II in specific receptors, not having the same action. Binding is long-lasting.
Has no tropism for other receptor subtypes. Reduces the content of aldosterone in the blood, does not inhibit renin in the plasma and ion channels in the cells.
The onset of an antihypertensive effect occurs within the first three hours after taking Telmisartan. The action persists for a day or more. The expressed effect develops in a month after constant reception.
In persons with arterial hypertension Telmisartan reduces systolic and diastolic pressure, but does not change the number of heartbeats.
It does not cause withdrawal syndrome.
Pharmacokinetics of Micardis hct.
Micardis hct can be purchased on our site in any quantities.
When taken orally, it is quickly absorbed from the intestine. Bioavailability is approaching 50%. After three hours, the concentration in the plasma becomes maximum. 99.5% of the active substance binds to blood proteins. It is metabolized by reacting with glucuronic acid. Metabolites of the drug are inactive. The half-life is more than 20 hours. Output through the digestive tract, excretion in the urine is less than 2%.
Indications for use of Micardis hct.
Reduction of cardiological morbidity and mortality in persons over 55 years of age at risk.
Contraindications of Micardis hct.
Micardis hct tablets are contraindicated for persons with allergies to the components of the drug, severe hepatic or kidney disease, intolerance to fructose, during pregnancy and lactation, to children under 18 years of age.
Side effects of Micardis hct.
From the central nervous system: depression, dizziness, headache, fatigue, anxiety, insomnia, convulsions.
On the part of the respiratory system: diseases of the upper respiratory tract (sinusitis, pharyngitis, bronchitis), cough.
On the part of the circulatory system: marked lowering of pressure, tachycardia, bradycardia, chest pain.
On the part of the digestive system: nausea, diarrhea, dyspepsia, increased concentration of hepatic enzymes.
From the musculoskeletal system: myalgia, back pain, arthralgia.
On the part of the genitourinary system: edema, infection of the genitourinary system, hypercreatininaemia.
Hypersensitivity reactions: skin rash, angioedema, hives.
Laboratory indicators: anemia, hyperkalemia.
Other: erythema, itching, dyspnea.
Micardis hct, instructions for use when purchasing on our site you buy the original product.
According to the instructions for use of Micardis hct, the drug is taken orally. Adults recommended a dose of 40 mg once a day. In a number of patients, the therapeutic effect is already observed with a dose of 20 mg per day. If the pressure drops to the desired level is not observed, the dose can be increased to 80 mg per day.
The maximum effect of the drug is achieved five weeks after the start of therapy.
In patients with severe forms of hypertension, it is possible to use 160 mg of the drug per day.
Overdose with Micardis hct
Symptoms: excessive lowering of blood pressure.
Telmisartan activates the hypotensive effect of other means of lowering the pressure.
With the joint use of telmisartan and digoxin, a periodic determination of the digoxin concentration in the blood is necessary, since it can be increased.
With the joint administration of lithium drugs and ACE inhibitors, a temporary increase in the lithium content in the blood, manifested by toxic action, can be observed.
Treatment with nonsteroidal anti-inflammatory drugs along with Mikardis in dehydrated patients can lead to the development of acute renal failure.